Beclomethasone Dipropionate in Preventing Acute Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant for Hematologic Cancer

You may be eligible if

• Inclusion
• Allogeneic HCT with marrow or growth-factor mobilized blood cells from an HLA-A, B, C, DRB1, and HLA-DQB1-allele matched or single-allele or antigen mismatched related or unrelated donor
• Use of myeloablative pre-transplant conditioning regimen with \> 800 cGy total body irradiation and cyclophosphamide, or high-dose busulfan and cyclophosphamide
• Use of methotrexate and tacrolimus for prevention of GVHD after allogeneic HCT
• Informed consent document signed
• Exclusion
• Cord blood transplant recipients
• Use of T cell depletion or rabbit antithymocyte globulin to prevent acute GVHD
• Treatment with rabbit antithymocyte globulin or alemtuzumab within 3 months before the date of HCT
• Participation in another therapeutic trial where the primary endpoint is related to acute GVHD
• Hospitalization at the beginning of the pre-transplant conditioning regimen because of pre-existing medical complications
• Glucocorticoid treatment at prednisone-equivalent doses \> 0.2 mg/kg/day
• Known intolerance to BDP
• Anticipated inability to tolerate oral administration of study drug tablets for any reason during the first two weeks after HCT
• Body weight \< 35 kg (lower-dose formulations are not available for subjects with lower body weight)
• Pregnancy or breast feeding
• Women of child-bearing potential who are unwilling to use a reliable method of contraception
• Incarceration